

Table S1. Clinical Variables Training Dataset

Variable	Overall Dataset	EGFR Mutant	EGFR Wildtype	KRAS Mutant	KRAS Wildtype
Median Age (Range)	69 46 - 85	71 62 - 85	69 46-84	68 50 - 81	69 46 - 85
Gender					
Male	59 (83%)	6 (8%)	53 (75%)	14 (20%)	45 (63%)
Female	12 (17%)	3 (4%)	9 (13%)	2 (3%)	10 (14%)
Smoking Status					
Current	16 (23%)	1 (1%)	15 (22%)	6 (8%)	10 (15%)
Former	47 (66%)	6 (8%)	41 (58%)	10 (14%)	37 (52%)
Non-smoker	8 (11%)	2 (3%)	6 (8%)	0 (0%)	8 (11%)
Pathological T Stage					
Tis	3 (4%)	1 (1%)	2 (3%)	0 (0%)	3 (4%)
T1a	16 (23%)	1 (1%)	15 (22%)	4 (6%)	12 (17%)
T1b	16 (23%)	3 (4%)	13 (19%)	3 (4%)	13 (19%)
T2a	23 (32%)	3 (4%)	20 (28%)	5 (7%)	18 (25%)
T2b	3 (4%)	0 (0%)	3 (4%)	1 (1%)	2 (3%)
T3	6 (8%)	1 (1%)	5 (7%)	3 (4%)	3 (4%)
T4	4 (6%)	0 (0%)	4 (6%)	0 (0%)	4 (6%)
Pathological N Stage					
N0	54 (76%)	8 (11%)	46 (65%)	12 (17%)	42 (59%)
N1	8 (11%)	1 (1%)	7 (10%)	1 (1%)	7 (10%)
N2	9 (13%)	0 (0%)	9 (13%)	3 (4%)	6 (9%)
Pathological M Stage					
M0	69 (97%)	9 (13%)	60 (84%)	15 (22%)	54 (75%)
M1b	2 (3%)	0 (0%)	2 (3%)	1 (1%)	1 (2%)
Histology					
Adenocarcinoma	54 (76%)	9 (13%)	45 (63%)	15 (22%)	39 (54%)
Squamous cell carcinoma	14 (20%)	0 (0%)	14 (20%)	0 (0%)	14 (20%)
NSCLC NOS	3 (4%)	0 (0%)	3 (4%)	1 (1%)	2 (3%)

Table S2. Clinical Variables Test Dataset

Variable	Overall Dataset	EGFR Mutant	EGFR Wildtype	KRAS Mutant	KRAS Wildtype
Median Age (Range)	67 50 - 81	79 55 - 81	65 50 - 81	67 65 - 79	65 55 - 81
Gender					
Male	6 (50%)	1 (8%)	5 (42%)	3 (25%)	3 (25%)
Female	6 (50%)	2 (17%)	4 (33%)	1 (8%)	5 (42%)
Smoking Status					
Current	2 (17%)	0 (0%)	2 (17%)	0 (0%)	2 (17%)
Former	9 (75%)	2 (17%)	7 (58%)	4 (33%)	5 (42%)
Non-smoker	1 (8%)	1 (8%)	0 (0%)	0 (0%)	1 (8%)
Pathological T Stage					
Tis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
T1a	1 (8%)	0 (0%)	1 (8%)	0 (0%)	1 (8%)
T1b	3 (25%)	2 (17%)	1 (8%)	0 (0%)	3 (25%)
T2a	3 (25%)	0 (0%)	3 (25%)	2 (17%)	1 (8%)
T2b	3 (25%)	1 (8%)	2 (17%)	0 (0%)	3 (25%)
T3	2 (17%)	0 (0%)	2 (17%)	2 (17%)	0 (0%)
T4	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Pathological N Stage					
N0	11 (92%)	2 (17%)	9 (75%)	4 (34%)	7 (58%)
N1	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
N2	1 (8%)	1 (8%)	0 (0%)	0 (0%)	1 (8%)
Pathological M Stage					
M0	11 (92%)	3 (25%)	8 (67%)	4 (34%)	7 (58%)
M1b	1 (8%)	0 (0%)	1 (8%)	0 (0%)	1 (8%)
Histology					
Adenocarcinoma	12 (100%)	12 (100%)	12 (100%)	12 (100%)	12 (100%)
Squamous cell carcinoma	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
NSCLC NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)